Novartis MS Pill Beats Older Drug in Clinical Trials

Novartis reports its oral drug remibrutinib successfully reduced relapses in multiple sclerosis patients during late-stage trials. The positive results boost hopes for the companys drug pipeline and potential blockbuster sales.

Xurve View
Insights:
People use VR goggles at the Novartis booth during the China International Supply Chain Expo (CISCE) in Beijing, China June 22, 2026. REUTERS/Florence Lo

NOVARTIS AG-REG said remibrutinib beat an older multiple sclerosis treatment in two late-stage trials, boosting peak sales expectations to $9 billion. The Swiss drugmaker's shares rose 4% following the announcement during Tuesday's trading session. The positive data provides a key pipeline boost as the company faces generic competition for its blockbuster heart-failure drug Entresto.